Roche Pharmaceutical Development and Sales Overview
YTD Sep 2022: Diagnostics Division sales
Sales increase of +6% driven by base business and COVID-19 testing
2022
2021
Change in %
CHFM
CHFM
CHF
CER
Diagnostics Division
13,848
13,305
4
6
Core Lab¹
5,833
5,677
3
5
Point of Care 1
3,086
2,415
28
30
Molecular Lab¹
2,735
3,030
-10
-8
Diabetes Care
1,219
1,294
-6
-3
Pathology Lab
975
889
10
10
Roche
CER-Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +5%; 1 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the
Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
34
4View entire presentation